Similar articles

• Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.

  Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Ronconi S, Visani G, Baccarani M. Piccaluga PP, et al. Haematologica. 2003 Dec;88(12):ECR37. Haematologica. 2003. PMID: 14688010 No abstract available.
• Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.

  Mele A, Sparaventi G, Guiducci B, Nicolini G, d'Adamo F, Leopardi G, Delfini C, Piccaluga P, Visani G. Mele A, et al. Haematologica. 2004 Jun 1;89(6 Suppl):ECR18. Haematologica. 2004. PMID: 15194554 No abstract available.
• [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].

  Hirayama Y, Terui T, Koike K, Neda H, Ishitani K, Kohda K, Kuroda H, Iyama S, Sato T, Kobune M, Takimoto R, Kato J. Hirayama Y, et al. Rinsho Ketsueki. 2009 Aug;50(8):663-5. Rinsho Ketsueki. 2009. PMID: 19915382 Japanese.
• [Combination chemotherapy for acute myeloid leukemia].

  Nagai T. Nagai T. Nihon Rinsho. 2009 Oct;67(10):1921-5. Nihon Rinsho. 2009. PMID: 19860191 Review. Japanese.
• Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.

  Stadtmauer EA. Stadtmauer EA. Clin Lymphoma. 2002 Mar;2 Suppl 1:S24-8. doi: 10.3816/clm.2002.s.005. Clin Lymphoma. 2002. PMID: 11970767 Review.